Total 208, page 11/11
| No. | Organization | Therapeutic Area | Product Type | Title |
|---|---|---|---|---|
| 4 | Duke University | Immunology, Oncology | Small molecule | HS206, TAK1 Selective Inhibitor |
| 4 | Boston Children's Hospital | Cardiovascular disease | Protein | ApoM-Fc Fusion Protein in Complex with S1P for the Treatment of Vascular Diseases |
| 3 | Weill Cornell Medicine | Cardiovascular disease, Metabolic disease | Nucleotide | A MicroRNA Mimic for the Treatment of Familial Hypercholesterolemia and Atherosclerosis |
| 3 | Dana Farber | Oncology | Gene therapy | NLRC5 as a target to intervene MHC class 1 mediated immune responses |
| 2 | Dana Farber | Metabolic disease | Protein | PM20D1 as a key enzyme for energy expenditure |
| 2 | Weill Cornell Medicine | Musculoskeletal disease, Endocrinology | Protein | Targeting the SLIT3 Pathway to Promote Bone Formation |
| 1 | Dana Farber | Oncology | Small molecule | ERK5 inhibitor as key regulator in cancer treatment |
| 1 | NIH | Musculoskeletal disease | Protein | La Protein as a Novel Regulator of Osteoclastogenesis |
